InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（740 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
740
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Rothblatt Martine A, Founder, Chairperson, and Chief Executive Officer. Director active across 2 companies, notably UNITED THERAPEUTICS Corp. Cumulatively, 1,023 disclosures have been published. Split: 0 buy · 740 sells. Total volume traded: €286.7m. Activity tracked since 10 September 2021. The latest transaction was disclosed on 23 March 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Rothblatt Martine A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报1,023 总计
200 股@ US$524.41750.0005% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:11
9,500 股@ US$135.420.0058% mcap0.2% 占其流量Common StockSEC:0001106578-26-000131:0
480 股@ US$514.2570.0011% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:1
1,630 股@ US$515.45870.0038% mcap0.1% 占其流量Common StockSEC:0001106578-26-000131:2
2,386 股@ US$516.15710.0055% mcap0.2% 占其流量Common StockSEC:0001106578-26-000131:3
1,486 股@ US$517.10730.0035% mcap0.1% 占其流量Common StockSEC:0001106578-26-000131:4
1,346 股@ US$518.14340.0031% mcap0.1% 占其流量Common StockSEC:0001106578-26-000131:5
412 股@ US$519.19250.0010% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:6
751 股@ US$520.29750.0018% mcap0.1% 占其流量Common StockSEC:0001106578-26-000131:7
286 股@ US$521.58150.0007% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:8
517 股@ US$522.40220.0012% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:9
6 股@ US$523.4250.0000% mcap0.0% 占其流量Common StockSEC:0001106578-26-000131:10
9,500 股@ US$135.420.0058% mcap0.2% 占其流量Common StockSEC:0001106578-26-000130:0
704 股@ US$513.40120.0016% mcap0.1% 占其流量Common StockSEC:0001106578-26-000130:3
120 股@ US$514.32010.0003% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:4
240 股@ US$515.32990.0006% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:5
280 股@ US$517.07030.0007% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:6
642 股@ US$512.47140.0015% mcap0.1% 占其流量Common StockSEC:0001106578-26-000130:2
120 股@ US$531.120.0003% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:18
494 股@ US$511.57510.0011% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:1
200 股@ US$518.8940.0005% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:7
1,003 股@ US$520.2340.0024% mcap0.1% 占其流量Common StockSEC:0001106578-26-000130:8
477 股@ US$521.23560.0011% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:9
280 股@ US$522.40290.0007% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:10
240 股@ US$523.600.0006% mcap0.0% 占其流量Common StockSEC:0001106578-26-000130:11
1023 条申报中的 25 条
About Rothblatt Martine A
ROTHBLATT MARTINE A is Founder, Chairperson, and Chief Executive Officer, and also serves as Chairperson & CEO at UNITED THERAPEUTICS Corp and as Director at BETA Technologies, Inc. Across 598 filings in total, the 400 most recent filings cover the period from 2025-10-01 to 2026-07-09 and show only sales, for EUR 131333628; the listed filings are the 2026-05-01 filing at UNITED THERAPEUTICS Corp for EUR 1864504.520765315, the 2026-04-16 filing for EUR 1808146.280524264, the 2026-04-24 filing for EUR 1807397.69118175, the 2026-07-08 filing for EUR 1662326.708495125, the 2026-07-07 filing for EUR 1609987.382414076, and the 2026-04-27 filing for EUR 1558095.834488173.
